The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis

Hippokratia

Volumn 12, Issue 3, 2008, Pages 157-161

  Rasic Milutinovic, Z ^a   Perunicic Pekovic, G ^a   Cavala, A ^a   Gluvic, Z ^a   Bokan, L ^a   Stankovic, S ^b  

^a University Hospital Zemun   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

End stage renal disease; Erythropoietin; Il 6; Insulin resistance; Iron; TNF alpha

Indexed keywords

CYANOCOBALAMIN; FERRITIN; FOLIC ACID; GLUCOSE; HEMOGLOBIN; INSULIN; INTERLEUKIN 6; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANEMIA; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; IRON BINDING CAPACITY; IRON STORAGE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 46949083212     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-495
2. Yao Q, Lindholm, B, Stenvinkel P. Infammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis International 2004; 8: 118-129
3. Frank H, Heusser K, Höffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 2004; 66: 832-840
4. 3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357
5. Rasic-Milutinovic Z, Peruničić-Peković G, Plješa S, et al. Impaired insulin sensitivity and insulin secretion in hemodialysis patients with and without secondary hyperparathyroidism. Malta Medical Journal 2004; 16: 18-22
6. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A. Renal hemodynamics and sodium handling in moderate renal insuffciency: the role of insulin resistance and dyslipidemia. J Am Soc Nephrol 1995; 5: 1751-1760
7. Rasic-Milutinovic Z, Peruničić G, Plješa S, et al. Is insulin independent predictor of mortality in hemodialysis patients. Yugoslav Medical Biochemistry 2004; 23: 43-49
8. Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Ilic M, Stokić E. Metabolyc syndrome in HD patients: association with body composition, nutritional status, infammation and serum iron. Intern Med 2007; 46: 945-951
9. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intimamedia thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
11. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992; 61:377-382
12. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and hyperinsulinemia in uremia. Am J Physiol 1996; 270: F839-F844
13. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on hemodialysis. Nephrol Dial Transplant 1993, 8: 93-95
14. Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcome in hemodialysis patients. J Am Soc Nephrol 2002 ; 13: 734-744
15. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 1990; 5: 130-134
16. Bayés B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, infammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephol Dial Transplant 2006; 21: 984-890
17. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 2004; 36: 716-720
18. Spaia S, Pangalos M, Askepidis N, et al. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000; 84: 320-325
19. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of infammation, nutrition and iron in hemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149
20. Rogers JT, Bridges KR, Durmowicz GP, Glass J, Auron PE, Munro HN. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 1990; 265: 14572-14578
21. Zoccali C, Mallamaci F, Tripepi G. Infammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplan 2004; 19 (Suppl 5): 67-72
22. Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 2007; 22: 2554-2562
23. Shoji T, Nishizawa Y. Chronic kidney disease as a metabolic syndrome with malnutrition-need for strict control of risk factors. Intern Med 2005; 44: 179-187
24. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999; 107: 119-125
25. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A.Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 1995; 270: 23780-23784
26. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/ phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006; 17: 1388-1394
27. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 1994: 269: 3568-3573
28. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55(Suppl 2): S9-S15
29. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-42398
30. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-infammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
31. Aguilera A, Bajo MA, Diez JJ, et al. Effects of human recombinant erythropoietin on infammatory status in peritoneal dialysis patients. Adv Perit Dial 2002; 18: 200-205